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Background: The purpose of this study was to assess the acute ablative characteristics of
transurethral convective water vapor (steam) using the Rezūm® system in men with benign
prostatic hyperplasia through histologic and radiographic studies.
Methods: Seven patients were treated with transurethral intraprostatic injections of sterile
steam under endoscopic visualization followed by previously scheduled adenectomies.
The extirpated adenomas were grossly examined followed by whole mount sectioning and
staining with triphenyl-tetrazolium chloride (TTC) to evaluate thermal ablation. Histology
was performed after hematoxylin and eosin staining on one prostate. After review of
results from the first patient cohort, an additional 15 patients with clinical benign prostatic
hyperplasia were treated followed by gadolinium-enhanced magnetic resonance imaging
(MRI) at one week.
Results: In the first patient cohort, gross examination of TTC-stained tissue showed thermal
ablation in the transition zone. In addition, there was a distinct interface between viable and
necrotic prostatic parenchyma. Histopathologic examination revealed TTC staining-outlined
necrotic versus viable tissue. Gadolinium-enhanced MRIs in the cohort of 15 patients demonstrated lesion defects in all patients at 1 week post-procedure. Coalesced lesions were noted
with a mean (± standard deviation) lesion volume of 9.6±8.5 cm3. The largest lesion volume
was 35.1 cm3. Ablation using vapor was rapid and remained confined to the transition zone,
consistent with the thermodynamic principles of convective thermal energy transfer.
Conclusion: Thermal ablation was observed in all specimens. The resulting coalescing ablative lesions, as seen on MRI, were confined to the transition zone. These studies confirm the
ablative capabilities of vapor, validate the thermodynamic principles of convective heating, and
allow for further clinical studies.
Keywords: steam, vapor therapy, thermotherapy, minimally invasive, lower urinary tract
symptomatology, benign prostatic hyperplasia
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The Rezūm® system is a minimally invasive treatment for lower urinary tract symptomatology utilizing the unique properties of convective energy transfer as described
by the laws of thermodynamics. This contrasts with the conductive characteristics
of other minimally invasive therapies such as transurethral microwave and radio
frequency modalities. Convection is the movement of a heated gas or liquid within a
13
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defined space. Steam (vapor) fills a defined space between
the cells and transfers energy onto the exterior of cell
membranes. Conduction is the transfer of heat through a
nonmoving material from the area of higher temperature to
lower temperature.1
The Rezūm system, via a transurethral approach, injects
water vapor into the transition zone of the prostate at
approximately 103°C. The vapor disperses through the tissue
interstices using infusion pressures slightly above interstitial
pressure and convectively delivers thermal energy, while
staying contained within the transition zone.
When heated to steam, water expands approximately
1,700 times its liquid volume and carries up to 540 calories of
energy per gram. This stored thermal energy is released when
steam phase shifts or condenses from vapor to liquid upon
contact with tissue. The temperature of tissue treated with
vapor in the 9-second treatment has been demonstrated to
reach between 70°C and 80°C,2 consistent with the temperature range at which cell death occurs instantaneously.3
The objective of the early studies reported herein was to
determine whether convective thermal energy transfer resulting from vapor delivery by the Rezūm system was capable
of rapid and effective ablation of human prostate tissue. To
validate the principles of convective steam delivery to treat
lower urinary tract symptoms (LUTS) due to benign prostatic
hyperplasia (BPH) and assess the ablative characteristics,
a series of histological and radiographic studies were performed in two initial studies. In the first study, a histological
vital stain was used on extirpated prostate tissue to demarcate
viable and necrotic tissue previously treated with the Rezūm
system. In the second study, gadolinium-enhanced magnetic
resonance imaging (MRI) was performed 1 week following
treatment with the Rezūm system to visualize the ablative
effect and to evaluate location of the resultant lesions.

Materials and methods
All human studies were approved by the appropriate ethics
committee and were therefore performed in accordance with
the ethical standards laid down in the 1964 Declaration of
Helsinki and its later amendments. All subjects gave their
informed consent prior to their inclusion in the study.
Under ethics committee approval from a single treatment
center, 22 men were recruited from a cohort of patients with
symptomatic BPH. Patients were excluded if they had a penile
prosthesis, any prior minimally invasive BPH procedure, confirmed or suspected prostate carcinoma, prior radiation therapy,
urethral strictures, or a biopsy of the prostate within 30 days,
or were unable or unwilling to provide informed consent.
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Table 1 Baseline patient characteristics for the first patient
cohort (n=7)
Parameter

Mean (SD), median (range)

Age, years
70.4 (4.2), 69.0 (66.0–78.0)
Pretreatment TRUS prostate measurements, cm
Width
4.92 (1.15), 4.40 (3.90–7.20)
 Height
3.79 (0.89), 3.40 (2.80–4.90)
 Length
4.83 (1.17), 4.80 (3.10–6.80)
Volume (cm3)
51.2 (34.7), 39.8 (19.5–125.5)
Abbreviations: SD, standard deviation; TRUS, transrectal ultrasound.

The Rezūm system generates vapor by application of
radiofrequency energy to create heat via electromagnetic
induction in the handle of the delivery device and incorporates a standard endoscopic cystoscopy lens to visualize
the positioning of the treatment needle into the obstructing
BPH tissue. A PEEK (polyether ether ketone) needle is
smoothly and rapidly deployed under direct visualization
into the obstructive regions of the transition zone and the
steam is delivered into the tissue from an array of vapor
emitter holes spaced 120 degrees circumferentially around
the tip of the needle. Each injection of steam is for approximately 9 seconds. The number of injections in each prostate
is determined by the size of the adenoma and length of the
prostatic urethra.
In the first study, seven patients scheduled for surgical
removal of prostate tissue were treated with transurethral
steam therapy under the same anesthetic as for the planned
open adenectomy (Table 1). The number of steam injections
was determined by prostatic urethral length and presence/
absence of a median lobe. Following treatment with
vapor, adenectomies were performed and the fresh, extirpated
adenomas were grossly examined followed by immediate
whole mount sectioning and preparation for and staining
with triphenyl-tetrazolium chloride (TTC). TTC stains viable
tissue with healthy metabolic enzymes as a bright red color,
while irreversibly damaged tissue with no metabolic enzymes
does not take up stain and remains its natural tan color.4
Table 2 Baseline patient characteristics for the second patient
cohort (n=15)
Parameter

Mean (SD)

Median (range)

Age, years
Prostate volume (cm3)
IPSS
QoL score
Qmax (mL/sec)
PVR (mL)*

69.9 (8.8)
49.7 (19.6)
23.6 (6.6)
4.1 (1.7)
7.7 (3.1)
82.8 (75.4)

68 (58–90)
46.0 (23.7–100.3)
21 (15–34)
5 (0–6)
8 (2–15)
50.7 (20–277)

Note: *Data available for 13 patients only.
Abbreviations: SD, standard deviation; IPSS, International Prostate Symptom
Score; QoL, quality of life; Qmax, maximum flow rate; PVR, post-void residual.
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Table 3 Treatment parameters
Patient cohort
First
 Injections per lobe, right
 Injections per lobe, left
 Injections per lobe, median
Second
 Injections per lobe, right
 Injections per lobe, left
 Injections per lobe, median

n

Mean (SD)

Median (range)

7
7
2

4.0 (1.0)
4.3 (1.4)
3.0 (0.0)

4.0 (3.0–6.0)
4.0 (3.0–6.0)
3.0 (3.0–3.0)

15
15
4

2.3 (0.7)
2.4 (0.8)
2.5 (0.6)

2.0 (1.0–4.0)
2.0 (1.0–4.0)
2.5 (2.0–3.0)

Abbreviation: SD, standard deviation.

Selected areas from the TTC-stained fresh whole mounts
of one prostate were then dissected and preserved in 10%
formalin for standard hematoxylin and eosin (H&E) staining.
Histological analysis was used to demarcate viable and
necrotic tissue as well as areas of interest such as the urothelium and thermal boundaries.
After analyzing extirpated tissues from the first seven
patients, another ethics committee protocol was approved
for a second cohort of 15 patients (Table 2). The only relevant difference in inclusion/exclusion criteria between the
two patient cohorts was that patients in the second group
were to have their BPH treated with the Rezūm system
without undergoing adenectomy. While there were other
standard exclusion criteria unique to the second cohort
A

(eg, concomitant use of medications, bladder or sphincter
abnormalities), these additional criteria were related to
the long-term clinical follow-up of these patients, which
is not reported herein. Gadolinium-enhanced MRI was
performed on each subject 1 week posttreatment to assess
volume and location of the ablative lesions. The MRIs were
analyzed by the Mayo Clinic Biomedical Image Resource
using Analyze 10.1™ software, and three-dimensional
volumetric renderings were created to measure the prostate,
transition zone, and areas of treatment as indicated by the
gadolinium defect.

Results
In the adenectomy group, the mean number of steam injections per lateral lobe was 4.1 (range 3–6), and the median
lobe was treated in two patients (Table 3). There were no
thermal effects seen outside of the prostate at the time of
adenectomy on gross examination. Each extirpated adenoma
showed defects identified by vital staining that correlated
with the injection sites. The treatments coalesced and
produced lesions in the transition zones visible via vital
staining. Lesions were observed in the tissue and the tissue
was sectioned axially (Figure 1A). The largest lesions from
each adenoma averaged 18.0 mm ×18.9 mm, with the largest
lesion being 21 mm ×28 mm (Figure 1B).

B

Anterior

Left lateral

Right lateral

Posterior

Figure 1 (A) Adenoma removed from suprapubic prostatectomy, whole mount sectioned, and stained with triphenyl-tetrazolium chloride. Note the distinct interface
between the red viable tissue and the tan nonviable tissue from the steam injections. (B) Close-up of slice 7 from Figure 1A. The red box outlines the right transition zone
and is used for histology in Figure 2A–C. Note the urethra is preserved and the maximum lesion size is 2.1 cm ×2.8 cm.
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Figure 2 (A) Whole mount hematoxylin and eosin section of the right lobe outlined by the red box is seen in Figure 1B. (B) Hematoxylin and eosin micrograph at 10× magnification
taken at the interface between the viable (left side of the green line) and necrotic prostatic parenchyma (right side of the green line) identified by triphenyl-tetrazolium chloridestaining and confirmed by microscopic evaluation. (C) 20× magnification identifying foci of thrombosed vasculature scattered throughout the necrotic prostate.

H&E histologic staining of the one excised adenoma
tissue demonstrated distinct demarcations between nonviable treated tissue and untreated prostate. This correlated
well with TTC whole mount specimens (Figure 2A and B).
H&E also demonstrated thrombosed vasculature (Figure 2C)
and general preservation of the prostatic urethral epithelium

A

(Figure 3A and B). There was no carbonization or heat fixation observed in the excised tissue.
In the Rezūm system-treated group without adenectomy,
the mean number of steam injections per lateral lobe was
2.3 (range 1–4) and the mean number of injections per
median lobe in four patients was 2.5 (range 2–3; Table 3).

B
Urethral epithelium

10x
50µm

Figure 3 (A) Whole mount hematoxylin and eosin section of the left lobe. (B) Preservation of urethral epithelium at 10× magnification.
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Table 4 Lesion characteristics
Lesion volume

n

Mean (SD)

Median (range)

15

9.6 (8.5)

6.8 (3.1–35.1)

Abbreviation: SD, standard deviation.

The MRIs of these 15 treated patients demonstrated prostatic
gadolinium defects in all patients at 1 week from therapy. This
merging of treatment zones appeared to mimic that which
was observed using TTC staining on adenectomy whole
mount specimens. Coalesced lesions were noted in each

lateral lobe corresponding to the targeted treatment sites. At
1 week, the mean (± standard deviation) gadolinium defect
volume was 9.6±8.5 cm3 (Table 4). The largest defect volume
was 35.1 cm3 (Figure 4A and B). Gadolinium defects have
been shown to correlate with histological proven necrosis
in previous studies.5 Defects were observed in the transition
zone. No thermal effects were seen in the peripheral zone. In
several cases, the gadolinium defect outlined the boundary of
the transition zone without passing through to the peripheral
zone (Figure 5A and B).

Figure 4 (A) Gadolinium-enhanced coronal magnetic resonance imaging showing large thermal lesions contained within the transition zone bilaterally. (B) Three-dimensional
volumetric renderings based on the magnetic resonance imaging data.
Notes: Yellow, total prostate volume; brown, total transition zone; green, right thermal lesion; blue, left thermal lesion; total volume of necrosis =35.1 cm3.
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Discussion
By observing both TTC-stained whole mounts and MRIs
of the treated tissues, we conclude that 9-second treatments
of transurethral convective heating with water vapor can
rapidly ablate human prostate tissue in the transition zone.
Because of the convective thermal transfer using steam,
lesions were observed within the McNeal zones of the prostate where the steam had been injected.6 These properties
cause steam to travel through the interstices between cells
until it encounters boundaries. At the boundary, such as the
tissue planes between prostatic zones, steam will follow the

perimeter similar to the way wind blows against a sail without
penetrating. These unique properties are further supported
by MRIs of the 15 subjects demonstrating defects outlining
the transition zone and hyperplastic tissue without extension
into the peripheral zone.
In conclusion, significant ablation of prostatic tissue is
possible with convective steam treatments of approximately
9 seconds per injection. Further studies are warranted to
confirm the clinical benefit and safety of prostatic ablation
with steam.
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